Yesterday's announcement of the safe progression of the lead-in study using only the CD19 expressing oncolytic virus is also good news for Arovella (if the ALA-101 / onCARlytics in vivo trial is successful).
Yesterday's announcement of the safe progression of the lead-in...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $147.2M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 14.0¢ | $22.45K | 159.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 339531 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 59848 | 4 |
View Market Depth
| Last trade - 11.56am 12/08/2024 (20 minute delay) ? |
| ALA (ASX) Chart |